Ziopharm Oncology (ZIOP) Announces Proposed Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ziopharm Oncology (ZIOP) Prices 27.826M Share Common Offering at $3.25/Sh
February 7, 2020 5:59 AM ESTZiopharm Oncology, Inc. (Nasdaq: ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase up to an additional 4,173,912... More
Pre-Open Stock Movers 2/5: (ABUS) (COTY) (QGEN) Higher (PLT) (KN) (SNAP) Lower (more...)
February 5, 2020 9:15 AM ESTPre-Open Stock Movers
Plantronics (NYSE: PLT) 30% LOWER; reported Q3 EPS of $0.30, $0.16 better than the analyst estimate of $0.14. Revenue for the quarter came in at $392 million versus the consensus estimate of $400.51 million. Plantronics sees Q4 2020 EPS of ($0.36)-$0.19, versus the consensus of $0.51. Plantronics sees Q4 2020 revenue of $354-394 million, versus the consensus of $441 million.
Ziopharm Oncology (ZIOP) Prices 27.83M Share Common Offering at $3.25/Sh
February 5, 2020 9:03 AM ESTZiopharm Oncology, Inc. (NASDAQ: ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase up to an additional 4,173,912... More
